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Abstract 
Background: A variety of smartphone apps and wearables are available both to help patients monitor their health 
and to support health care professionals (HCPs) in providing clinical care. As part of the RADAR-CNS consortium, we 
have conducted research into the application of wearables and smartphone apps in the care of people with multiple 
sclerosis, epilepsy, or depression.
Methods: We conducted a large online survey study to explore the experiences of HCPs working with patients 
who have one or more of these conditions. The survey covered smartphone apps and wearables used by clinicians 
and their patients, and how data from these technologies impacted on the respondents’ clinical practice. The survey 
was conducted between February 2019 and March 2020 via a web-based platform. Detailed statistical analysis was 
performed on the answers.
Results: Of 1009 survey responses from HCPs, 1006 were included in the analysis after data cleaning. Smartphone 
apps are used by more than half of responding HCPs and more than three quarters of their patients use smartphone 
apps or wearable devices for health-related purposes. HCPs widely believe the data that patients collect using these 
devices impacts their clinical practice. Subgroup analyses show that views on the impact of this data on different 
aspects of clinical work varies according to whether respondents use apps themselves, and, to a lesser extent, accord-
ing to their clinical setting and job role.
Conclusions: Use of smartphone apps is widespread among HCPs participating in this large European survey and 
caring for people with epilepsy, multiple sclerosis and depression. The majority of respondents indicate that they treat 
patients who use wearables and other devices for health-related purposes and that data from these devices has an 
impact on clinical practice.
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Introduction
The easy availability and reduced cost of mobile and 
wearable technologies is enabling individuals to record 
more data about their physical and mental health than 
ever before. Digital health smartphone apps (soft-
ware installed and run on smartphones) are known to 
be used for a variety of healthcare-related purposes 
by both patients and clinicians. For example, a multi-
national online survey found that diabetes apps are 
used by over half of those with type 1 and one third of 
those with type 2 diabetes [1]. In a recent US study, just 
under half of survey respondents living with hyperten-
sion reported using apps to help manage it [2]. In rela-
tion to central nervous system disorders, their use has 
been explored in the management of depressive and 
bipolar disorders for mood monitoring and contextual 
prompting (‘THINC-IT’ [3], ‘True Colours’ [4], ‘Wear-
IT’ [5]), and systematic reviews of depression apps in 
2015 and 2020 identified digitized therapeutic interven-
tion, symptom tracking and psychoeducation as main 
functions of apps available for this market [6, 7]. In epi-
lepsy, apps are available for a range of purposes, includ-
ing to enter details of seizures to create a record (e.g. 
‘Seizure Tracker’) and to notify an emergency contact 
if a person living with epilepsy does not respond to a 
daily prompt (‘Snug Safety’ app). A systematic review of 
the Apple app store for epilepsy or seizure-related apps 
also identified education and seizure trigger recording 
as functions of the available apps [8]. Smartphone apps 
for multiple sclerosis include functions such as medi-
cation reminders and symptom trackers, in addition to 
assessment of function through games and question-
naires [9].
There are also a wide variety of apps available which 
are targeted at health care professionals (HCPs) [10], 
including apps providing clinical guidelines [11], apps 
with clinical task specific calculators [12], prescrib-
ing apps [13], and apps providing the ability for HCPs 
to communicate with each other and/or with patients 
and to inform decision-making. Both digital health 
apps aimed at patients and apps aimed at HCPs can be 
subject to regulation, depending on their intended pur-
pose, as they may be designated ‘software as a medical 
device’ [14].
A large variety of off-the-shelf wearable sensing 
devices are commercially available, aimed at the pub-
lic for the purpose of monitoring health and wellbe-
ing. These include electronic wristbands, pedometers 
and devices designed for specific conditions such as 
epilepsy seizure detection wristbands. Many of these 
interface with smartphone apps to provide greater func-
tionality. Wearable sensing devices allow their wearers 
to monitor many aspects of their daily lives, including 
steps taken, heart rate, sleep quality and duration, and 
exercise. As such, their use is generally for the ‘pas-
sive’ collection of data, without the user’s active input. 
Recently, their use as tools for monitoring patients with 
central nervous system disorders has garnered interest 
[15]. Prior work has shown that connected digital prod-
ucts are used increasingly in clinical trials [16], demon-
strating their value as tools to accurately record aspects 
of patient functioning. Patients themselves have a vari-
ety of views on the use of apps and wearables for moni-
toring specific conditions, including both benefits and 
challenges [17, 18].
When wearable devices and smartphone apps are used 
to collect data on human behaviour and physical param-
eters, these information-gathering tools are collectively 
described as remote measurement technology (RMT). 
The RADAR-CNS project, funded by Horizon 2020 and 
the Innovative Medicines Initiative, explores the poten-
tial of RMT in the clinical management of epilepsy, MS 
and depression. The consortium consists of a team of 
researchers, clinicians and a patient advisory board of 
individuals with lived experience of epilepsy, multiple 
sclerosis (MS), or depression (www. radar- cns. org). Pro-
ject outputs to date have provided insight into the poten-
tial benefits of incorporating RMT in clinical pathways, 
via qualitative surveys of patients and healthcare profes-
sionals within the consortium [19] and interviews with 
HCPs outside the consortium [20]. In these small studies, 
HCPs and patients envisaged multiple ways that RMT 
could permit both ‘active’ (direct user input of data, such 
as mood diaries) and ‘passive’ (collection of data with-
out the requirement of the user to input data, e.g. step 
count, GPS location) collection of data to remotely assess 
patients with these conditions.
This paper adds to this body of work by exploring the 
experiences of a much larger number of HCPs working 
with patients with epilepsy, MS, or depression outside 
the consortium. In studies relating to health care tech-
nology, exploring views from a wide range of health care 
professionals working across different job roles has the 
benefit of reducing bias in the self-selection of research 
participants with a particular interest in or positive dis-
position toward health care technology [21]. As such, the 
Keywords: Smartphone apps, Healthcare professionals, Depression, Multiple sclerosis, Epilepsy, Remote 
measurement technology, Survey
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present research study aimed to elicit opinions and expe-
riences from a broad sample of HCPs working in the care 
of patients with epilepsy, MS or depression.
The Covid-19 pandemic has seen the typical organisa-
tion of healthcare in England change to increase remote 
consultations in both primary [22] and secondary care 
[23] to reduce the risk of infection between patients and 
staff. It is therefore timely to explore opinions and experi-
ences of HCPs on the use of smartphone apps and RMT.
Methods
Surveys are often used to elicit data from large popula-
tions and have been used to capture the views of clini-
cians [24, 25]. Since they require a short amount of time 
to administer and provide the opportunity to collect both 
quantitative and qualitative data, a survey was considered 
to be the most appropriate tool to learn more about HCP 
experiences, where these individuals have busy schedules 
and value the ability to complete these at a time of their 
choosing.
We conducted a large-scale, online survey, admin-
istered using the JISC Online Surveys platform [26]. 
Informed consent was gathered through an information 
sheet and consent form at the beginning of the survey 
form. Ethical approval for this study was granted by the 
University of Nottingham research ethics committee (ref 
277-1802) and by the UK Health Research Authority (ref 
19/HRA/5041). Inclusion criteria were that respondents 
should be currently working in the care of people with 
epilepsy, MS or depression, within adult services.
Our main objectives in the present work were: (i) to 
determine the extent of smartphone app usage among 
health care professionals; (ii) to determine the extent of 
HCP experience of their patients’ use of RMT (including 
smartphone apps and wearables); and (iii) to understand 
the impact of patient RMT usage on HCPs’ work, includ-
ing how this may vary by demographic factors.
There were nine pages of questions in the survey (see 
Additional file  1), in two broad sections. Textbox  1 
shows a breakdown of sections of the survey. Survey 
questions were designed by the research team to reflect 
the goals of the research programme. Questions 1–7 
concerned participant consent. Questions 8–16 were 
developed through consultation with expert clinicians 
from each of the three specialties, together with con-
sideration of existing literature, in order to measure 
the value of various parameters for target conditions. 
Questions 17–26 were developed with consideration 
of potential scenarios of use between patients and cli-
nicians and considering key challenges highlighted by 
clinical and HCI researchers. Early questions prompted 
respondents to think about their existing use of apps in 
their work role before continuing with more focused 
aspects relevant to making RMT work in clinical prac-
tice. The survey was designed pragmatically to elicit 
data whilst ensuring an accessible survey to encourage 
participation by busy healthcare professionals.
The survey respondents took a mean of 12  minutes 
to complete the survey, and were required to do so in 
a single sitting. In addition to collecting demographic 
information (questions 3–7), the focus of the first sec-
tion of the survey was on current and past experience 
of HCPs’ use of smartphone apps and their patients’ 
use of RMT (smartphone apps and wearables). The sec-
ond section had a different focus, exploring the future 
potential of RMT and the requirements for its future 
implementation. In this paper, we present results relat-
ing only to HCPs’ current/past experience of using 
smartphone apps and the impact of their patients’ use 
of RMT on their clinical role.
Textbox 1. Survey overview
SECTION 1:
Page 1: Participant Information and Consent
Page 2: Demographics/Healthcare Professional Role
Page 3: Current use of digital services and devices in your role as a Health 
Care Professional
SECTION 2:
Page 4: Your thoughts about using digital devices for long term monitor-
ing of medical conditions
Page 5: Value of RMT
Page 6: Accessing and using the data
Page 7: Technical Support requirements
Page 8: Closing remarks
Demographic questions in the survey consisted of 
respondent age group; specialism; job role; clinical set-
ting; and country of employment. Job role was collected 
by free text box and during data analysis, participant-
provided job roles were sorted into the seven categories 
reported here. Ambiguous terms were categorised as ‘not 
specified’.
Question 8 required respondents to indicate whether 
they had used any kind of smartphone apps in their daily 
clinical practice (and if so, what genre of app). Question 9 
asked respondents to indicate whether they had experi-
enced their patients using different types of RMT devices 
(smartphone apps, wearable sensing devices or other 
devices) to improve or increase awareness of their health 
across six categories of purpose. Question 10 invited 
respondents to evaluate to what extent the data from 
patient’s RMT devices had an impact on the respondent’s 
clinical practice in five areas, each scored on a five-point 
Likert-style scale. The survey instrument is provided in 
Additional file 1.
The survey was disseminated via multiple routes:
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• The UK National Institute for Health Research 
(NIHR) Clinical Research Network
• A targeted social media campaign across multiple 
European countries
• Through the stakeholder group of the Innovative 
Medicines Institute (IMI)
• Snowballed through professional contacts of the 
RADAR-CNS consortium members working in five 
European countries.
The survey was translated from English into five 
European languages spoken in the countries where the 
research consortium for the project operated. The first 
response was received on the 4th February 2019 and the 
last was received on the 30th March 2020.
Statistical analysis
Data were analysed using SPSS v.26 and Stata SE 16.1. 
We used descriptive statistics to understand the rates 
of responses from different demographic groups. Chi-
squared tests were used to compare the rate of reported 
app usage (question 8) between different job roles and 
age groups, as well as to compare reported use of apps 
and devices by respondents’ patients. Responses to 
items in question 10, on the impact of patient RMT data 
on five aspects of clinical work, were dichotomised as 
1 for responses of ‘definitely’ or ‘sometimes’, and 0 for 
responses of ‘unsure’, ‘hardly’, and ‘never’. ‘Unsure’ was 
grouped with the negative polarity items since respond-
ents may have responded in this way if they did not have 
experience of using these technologies. Dichotomising 
the data rather than treating it as a 5-point scale had the 
benefit of resolving this ambiguity. For question 10 on the 
impact of RMT data on respondents’ clinical practice, 
univariate, then multivariate logistic regression was used 
to explore the effect of demographic variables and app 
usage on views of the impact of RMT data. A p-value of 
0.05 was considered significant. For each categorical vari-
able, the reference category chosen was the category with 
the largest number of responses. Missing responses were 
accounted for using multiple imputation, also conducted 
in STATA. 83 imputations were calculated for each miss-
ing entry, as the highest fraction of missing information 
(FMI) found in the analysis was 0.83 [27]. A sensitivity 
analysis was used to examine the influence of missingness 
on parameter estimates by comparing the consistency of 




Survey responses were received from 1009 HCPs. The 
greatest proportion of these were completed as a result 
of efforts to recruit via the UK National Institute for 
Health Research (NIHR) Clinical Research Network: 
21 National Health Service (NHS) healthcare trusts and 
Clinical Commissioning Groups (CCGs) across the UK 
advertised the survey to healthcare staff working with 
patients with epilepsy, MS or depression in their area. 
These trusts and CCGs reported that 650 staff had noti-
fied them that they had completed the survey, how-
ever it is likely a greater proportion of the total survey 
responses were obtained via this recruitment method, 
as it was not compulsory for respondents to notify their 
trust of their involvement. We did not include a sur-
vey item to ask where respondents had heard about the 
survey to preserve anonymity, so it is not possible to 
further attribute respondents to different recruitment 
methods.
Despite the survey being available in 5 European 
languages in addition to English, and efforts made to 
disseminate the survey to clinicians working in other 
countries (via social media, LinkedIn groups, contacts 
of the consortium, and via the Innovative Medicines 
Initiative steering group), the number of respondents 
reporting to be working in countries outside the UK 
was small (n = 30, 3% of total). These were analysed 
together with the UK responses as there were too few 
from each individual country to viably compare them 
statistically against the UK responses.
Data cleaning
Of the 1009 completed surveys, 1006 were retained for 
analysis. Reasons for exclusion were insincere comple-
tion of the survey (n = 1) and improper completion of 




Removed due to 
insincere compleon:
1




Survey responses for analysis:
1006
Fig. 1 STROBE flow chart showing included responses in the dataset
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Demographics
Table  1 shows a breakdown of the included survey 
responses by demographics. Age group categories fol-
lowed a normal distribution, with the largest number of 
respondents in the middle category (ages 41–50, n = 293, 
29% of respondents) and progressively fewer in older and 
younger age groups. The most frequently selected item 
under specialism was ‘mental health’ (n = 587, 38%), with 
the fewest selecting ‘social care’ (n = 32, 2%). Although 
relatively few respondents reported a specialism of ‘mul-
tiple sclerosis’ (n = 55, 4%) or ‘epilepsy’ (n = 73, 5%), a 
larger number reported working in neurology (n = 112, 
7%), which is a specialism covering both these condi-
tions. Among job roles, ‘nursing’ was the category with 
the largest proportion of responses. Doctors would have 
been the second most numerous category, however doc-
tors were split into two categories of ‘GPs’ (n = 118, 12%) 
and ‘Doctor (excluding GP)’, (n = 138, 14%). ‘Clinical psy-
chology professionals’ were therefore the second most 
numerous category, with 157 responses (16%). There 
was good representation from all clinical settings, with 
fewest (5%) from ‘specialist tertiary care’ settings, which 
might be expected due to their specialised nature. Most 
responses (97%) were from HCPs working in the UK. The 
second most reported country was Portugal, with 21 sur-
vey completions (2%).
Use of smartphone apps by clinicians
559 respondents (56%) indicated that they use digital 
health smartphone apps for at least one purpose in their 
clinical role. Figure 2 shows the percentages of respond-
ents who reported using smartphone apps of each of the 
five types listed in this question. Guidelines apps were the 
most used (25%), while calculation apps were least used 
(11%). There was a spread of responses across all app 
types, with no app type receiving fewer than 10% of total 
responses.
Figure 3 shows the percentage of respondents in each 
job category who reported using smartphone apps in 
their daily clinical practice. A chi-squared test showed 
that there were significant differences between job 
roles for this question (χ2 = 106.348, p < 0.01). Pharma-
cists and medical students were most likely to report 
using any apps, although there were fewer survey com-
pletions overall from these job roles. Further analy-
sis revealed that of the different types of app listed, 











Mood disorders 121 12.0
Mental health 587 58.3
Epilepsy 73 7.3
Multiple sclerosis 55 5.5
Depression 165 16.4
General practice 152 15.1
Psychology 126 12.5
Social care 32 3.2
Other 119 11.8
Job role
Allied health professionals 112 11.1
Doctor (excl GP) 138 13.7
GP 118 11.7




Psychological professions 157 15.6
Student 10 1.0
Wider healthcare team 76 7.6
Not clear 48 4.8
Clinical setting
Primary care/general practice 193 19.2
Secondary care—hospital trust, inpatients 91 9.0
Secondary care—hospital trust, outpatients 82 8.2
Secondary care—mental health trust, inpatients 127 12.6
Secondary care—mental health trust, outpatients 254 25.2
Specialist tertiary care centre 54 5.3
Community care 173 17.2
Other 32 3.2
Country worked in
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pharmacists were most likely to report using prescrib-
ing/dosing apps (87% of pharmacist respondents), and 
medical students were most likely to use guidelines 
apps (80% of student respondents). 40% of GP respond-
ents and 38% of doctors excluding GPs reported using 
guidelines apps. Clinical psychology professionals and 
allied health professionals were least likely to report 
using smartphone apps of any kind.
Question 8a invited respondents to provide examples 
of other types of app that they used in their daily clini-
cal practice. Table  2 provides a random subsample of 
the responses, with information on the publisher, cat-
egory, cost and target condition of these, where relevant. 
Responses covered apps published by the NHS, chari-
ties, commercial organisations, and public bodies. Apps 








Fig. 2 Percentage of survey respondents who report using smartphone apps of each of these types on a daily basis in their professional role. Data 




















Fig. 3 Percentage of respondents in each job category who report using smartphone apps on a daily basis in their clinical practice
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health, with fewer focussed on neurological conditions, 
which could be expected given the larger proportion 
of responses from mental health specialists in the sam-
ple. Many of these apps are either patient-facing or have 
a focus on wellbeing and it is possible that respondents 
understood this question to mean apps they recommend 
to their patients, rather than apps they use themselves to 
facilitate their job role.
Across all age categories, between 50 and 60 percent of 
respondents reported using apps. The highest percentage 
was reported by those in the over-60 category. However, 
a chi-squared test on these age groupings was non-signif-
icant (χ2 = 1.848, p = 0.76).
Patient use of RMT for health‑related purposes
78% of respondents indicated that their patients used 
RMT (one or more of smartphone apps, wearables, or 
other type of device) to improve or increase awareness of 
their health. Figure 4 shows the relevant percentages for 
different purposes. Activity monitoring was selected by 
the largest proportion of respondents (62%). Sleep moni-
toring was also selected by more than half of respondents 
(53%). Of the given categories, monitoring for a specific 
condition was least selected (31%).
Figure 5 shows the split of these responses across dif-
ferent device types. Further to the above, this shows that 
wearable sensing devices are most commonly reported to 
be used for passive monitoring of activity and sleep, while 
smartphone apps were used more often than wearable 
devices for monitoring mood, setting personal health 
goals and weight management.
A sub-group analysis by job role showed that there 
were significant differences between job roles for this 
question (χ2 = 154.952, p < 0.01). This is shown in Fig. 6. A 
greater proportion of GPs than other types of health pro-
fessional had experienced their patients using devices to 
monitor activity (88% of GP respondents), monitor sleep 
(66%) and manage weight (66%).
Impact of RMT data on respondents’ clinical work
Sub-questions 10.1–10.5 asked respondents about the 
impact of the data from patients’ RMT devices on differ-
ent aspects of respondents’ clinical work. Figure 7 shows 
these results. Across all sub-questions, the mean percent-
age of respondents indicating that the data from RMT 
‘definitely’ or ‘sometimes’ had an impact on their work 
was 62%. The mean percentage of those indicating that it 
‘hardly’ or ‘never’ had an impact was 27%. A greater pro-
portion of respondents selected ‘definitely’ or ‘sometimes’ 
Table 2 A sample of names and types of smartphone apps reported by respondents who selected ‘other’ in response to a question on 
types of apps used in their daily clinical practice
App name/genre (as 
reported)




Survey apps Communication apps General N/A N/A
3d brain app Other Neurology DNA Learning Centre Free
British National Formulary Prescribing/dosing app General Indextra AB $69.99
Consultant-connect Communication General Consultant Connect Requires subscription by 
service
Headspace Consumer Wellbeing Headspace (company) Free, in-app subscription for 
more content
Calm Consumer Wellbeing Calm (company) Free, in-app subscription for 
more content
Medscape Other General WebMD Free, contains ads
Mindfulness apps Consumer Wellbeing N/A N/A
Observations apps Other General N/A N/A
distrACT Patient-facing Mental health Expert Self Care Ltd Free
Rise Up Patient-facing Mental health Recovery warriors Free




Mental health SilverCloud Health Free, requires referral
Stay Alive Patient-facing Mental health Grassroots Suicide Prevention Free
Symptom tracker Patient-facing General N/A N/A
Wellmind Patient-facing Mental health Blue Step Solutions Free
Young epilepsy Patient-facing Neurology Young epilepsy charity No longer available
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for sub-question 10.4 (Does RMT data impact patients’ 
awareness of their own health?) than for any of the other 
sub-questions.
Results from univariate and multivariate logistic 
regression analyses with multiple imputation and using 
questions 3–8 as independent variables and sub-ques-
tions 10.1–10.5 as dependent variables are provided in 
Tables  3, 4, 5, 6 and 7. An analysis for multicollinearity 
revealed no variance inflation factor (VIF) greater than 
3.5, suggesting that multicollinearity did not affect the 
results. Results from multiple imputation and observed 
datasets were consistent in term of the parameter esti-
mate and its precision.
Across all five sub-questions in question 10, the inde-
pendent variable on HCP use of smartphone apps 
(question 8), gave a significant result in the multivari-
ate logistic regression models, indicating that those 
respondents who reported using apps were more likely to 
respond with ‘definitely’ or ‘sometimes’ to the items dis-
cussing the impact of data from RMT on their work.
In relation to clinical setting, the reference category 
across all regression analyses in sub-questions 10.1 to 
10.5 was ‘primary care’. The univariate analyses showed 
that in all 5 sub-questions, respondents from at least 
one category of setting gave responses which were sig-
nificantly different to those in primary care. The odds 
ratios in these cases were below one, indicating that 
respondents working in multiple settings outside of pri-
mary care were less likely than those in primary care 
to respond positively (choose ‘definitely’ or ‘sometimes’ 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Other
Monitoring for a specific condion
Mood monitoring




Percentage of total respondents 
Fig. 4 Graph showing percentages of respondents who reported that their patients use smartphone apps, wearable sensing devices or other 










































Smartphone apps Wearable sensing device Other
Fig. 5 Percentages of survey respondents indicating that their patients use devices of these types for different purposes
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rather than ‘unsure’, ‘hardly’ or ‘never’) concerning the 
impact of RMT on their work. However, in the multi-
variate regression analyses, only 4 out of 5 sub-ques-
tions (10.1, 10.2, 10.4 and 10.5) showed significant 
differences between primary care and other settings, 
when other variables were controlled for.
With regard to job role, the reference category was 
‘doctors (excluding GPs)’. In 3 out of the 5 question 
items, the general practitioner job role was significantly 
different to the reference category (doctors excluding 
GPs) in the univariate regression analysis, however this 





















Not Specified Allied Health Professionals Doctor (excl GP) GP
Research / hcare science Management Nursing Pharmacy
Psychological professions Student Wider healthcare team































Definitely Somemes Unsure Hardly Never
Fig. 7 Percentages of item respondents for question items 10.1–10.6 indicating whether RMT data has an impact on five different aspects of their 
work
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sub-questions where other variables were controlled 
for.
In relation to age, only sub-question 10.5, concerning 
the impact of RMT data on decision-making processes 
in consultations, showed any difference between age 
groups. Here, according to both univariate and multi-
variate models, respondents in the 18–30 age category 
were less likely than those in the reference category (ages 
41–50) to indicate that patients’ RMT data had an impact 
on their decision-making processes during consulta-
tion. There was no significant difference between any 
specialism and the reference category (mental health) in 
the regression models for any of the question items.
Discussion
This study achieved its aim of eliciting views from a 
large sample of healthcare staff working in the care of 
patients with epilepsy, MS or depression. The results 
from this study have added to prior work in this area 
[19, 20] by showing that smartphone apps are used by 
more than half (56%) of HCPs and that more than three 
quarters (78%) report that their patients use RMTs for 
Table 3 Question 10.1—Does data from patients’ RMT impact your communication with patients?
Results from logistic regression with multiple imputation. Multiple imputation was used to impute data for this question item for 301 missing entries out of total 1006. 
Bold font indicates significant result
Question content/variable/category Multivariate model Univariate model
Impact of data on communication with patient OR (95% CI), p‑value OR (95% CI), p‑value
Q3—age
18–30 years 0.694 (0.432, 1.115), 0.1310 0.753 (0.494, 1.150), 0.1900
31–40 years 1.050 (0.697, 1.582), 0.8140 1.045 (0.705, 1.549), 0.8280
41–50 years Reference category Reference category
51–60 years 1.167 (0.755, 1.802), 0.4870 1.136 (0.746, 1.729), 0.5510
Over 60 years 1.121 (0.538, 2.336), 0.7600 1.198 (0.596, 2.405), 0.6120
Q4—specialism
Mental health Reference category Reference category
Neurology 0.999 (0.643, 1.553), 0.9980 1.031 (0.675, 1.574), 0.8880
Not specified 1.152 (0.789, 1.682), 0.4630 1.163 (0.810, 1.670), 0.4140
Q5—job role
Doctor excluding GP Reference category Reference category
Allied health professional 1.356 (0.712, 2.582), 0.3540 0.909 (0.510, 1.621), 0.7470
Not specified 1.269 (0.606, 2.657), 0.5280 1.065 (0.517, 2.194), 0.8640
GP 1.453 (0.624, 3.382), 0.3860 2.006 (1.125, 3.577), 0.0180
Research/healthcare scientist 0.592 (0.214, 1.638), 0.3130 0.475 (0.182, 1.240), 0.1280
Management 0.730 (0.322, 1.658), 0.4520 0.685 (0.314, 1.495), 0.3420
Nursing 1.289 (0.776, 2.141), 0.3270 1.055 (0.664, 1.676), 0.8220
Pharmacy 1.364 (0.286, 6.494), 0.6960 1.598 (0.356, 7.184), 0.5400
Clinical psychology professional 1.272 (0.718, 2.256), 0.4100 0.910 (0.548, 1.512), 0.7170
Student 2.822 (0.427, 18.635), 0.2810 1.996 (0.330, 12.062), 0.4510
Wider healthcare team 1.166 (0.571, 2.380), 0.6730 0.956 (0.496, 1.843), 0.8930
Q6—setting
Primary care Reference category Reference category
Secondary Care—hospital inpatient 0.688 (0.322, 1.470), 0.3350 0.584 (0.317, 1.073), 0.0830
Secondary care—hospital outpatient 0.750 (0.338, 1.666), 0.4800 0.621 (0.340, 1.133), 0.1210
Secondary care—MH inpatient 0.846 (0.411, 1.742), 0.6500 0.694 (0.407, 1.183), 0.1790
Secondary care—MH outpatient 0.588 (0.323, 1.069), 0.0820 0.460 (0.299, 0.706), 0.0000
Specialist tertiary care 1.013 (0.408, 2.515), 0.9780 0.747 (0.363, 1.540), 0.4290
Community care 0.462 (0.237, 0.900), 0.0230 0.414 (0.256, 0.668), 0.0000
Other 0.505 (0.187, 1.361), 0.1760 0.400 (0.172, 0.933), 0.0340
Q8—Uses apps in daily clinical practice
No Reference category Reference category
Yes 1.697 (1.202, 2.398), 0.0030 1.727 (1.262, 2.365), 0.0010
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health-related purposes. These figures are greater than in 
previous research studies that surveyed the use of apps 
in treatment by healthcare professionals working in epi-
lepsy, where 45% of respondents previously reported 
using apps with their patients [28], and in depression, 
where 21.2% of respondents in a prior study stated they 
used apps in treatment for depression [25]. Our findings 
thus may indicate their growing use in clinical practice 
(no prior evidence is available on clinicians’ use of apps 
in MS).
HCPs reported that their patients use smartphone apps 
for the purposes of: managing weight; setting personal 
health goals; and monitoring sleep, activity and mood. 
Wearable sensing devices are used by their patients for 
sleep and activity monitoring, and a smaller percentage 
report patient use of these devices for weight manage-
ment and monitoring a specific condition (Fig.  5). The 
majority of HCPs (mean average 62%) indicated that 
the data from these RMTs impacts their clinical practice 
and also indicated that RMT data has an impact on their 
Table 4 Question 10.2—Does data from patients’ RMT impact your understanding of patient health state at consultation?
Results from logistic regression with multiple imputation. Multiple imputation was used to impute data for this question item for 301 missing entries out of total 1006. 
Bold font indicates significant result
Question content/variable/category Multivariate model Univariate model
Impact of data on understanding of patient health state at 
consultations
OR (95% CI), p OR (95% CI), p
Q3—age
18–30 years 0.721 (0.435, 1.196), 0.2050 0.757 (0.480, 1.193), 0.2290
31–40 years 0.857 (0.557, 1.321), 0.4850 0.814 (0.542, 1.225), 0.3240
41–50 years Reference category Reference category
51–60 years 1.236 (0.827, 1.847), 0.3020 1.174 (0.799, 1.725), 0.4150
Over 60 years 1.285 (0.596, 2.772), 0.5220 1.307 (0.639, 2.672), 0.4620
Q4—specialism
Mental health Reference category Reference category
Neurology 0.720 (0.467, 1.108), 0.1350 0.756 (0.503, 1.137), 0.1790
Not specified 0.983 (0.670, 1.442), 0.9300 1.006 (0.700, 1.446), 0.9750
Q5—job role
Doctor excluding GP Reference category Reference category
Allied health professional 0.898 (0.490, 1.647), 0.7280 0.599 (0.343, 1.048), 0.0730
Not specified 1.160 (0.532, 2.526), 0.7090 0.958 (0.449, 2.045), 0.9130
GP 1.051 (0.459, 2.409), 0.9060 1.453 (0.820, 2.574), 0.2000
Research/healthcare scientist 0.460 (0.161, 1.314), 0.1470 0.340 (0.124, 0.933), 0.0360
Management 0.624 (0.258, 1.506), 0.2940 0.598 (0.260, 1.378), 0.2270
Nursing 1.282 (0.770, 2.133), 0.3390 1.071 (0.669, 1.715), 0.7740
Pharmacy 1.057 (0.245, 4.565), 0.9410 1.333 (0.327, 5.428), 0.6880
Clinical psychology professional 0.856 (0.471, 1.556), 0.6100 0.637 (0.376, 1.078), 0.0930
Student 2.520 (0.343, 18.501), 0.3630 1.867 (0.277, 12.579), 0.5210
Wider healthcare team 0.950 (0.477, 1.891), 0.8840 0.778 (0.413, 1.466), 0.4370
Q6—setting
Primary care Reference category Reference category
Secondary care—hospital inpatient 0.763 (0.347, 1.676), 0.5000 0.732 (0.397, 1.351), 0.3190
Secondary care—hospital outpatient 0.680 (0.321, 1.438), 0.3120 0.658 (0.375, 1.157), 0.1460
Secondary care—MH inpatient 0.754 (0.371, 1.535), 0.4360 0.719 (0.431, 1.201), 0.2070
Secondary care—MH outpatient 0.656 (0.356, 1.209), 0.1760 0.558 (0.364, 0.856), 0.0070
Specialist tertiary care 0.858 (0.367, 2.005), 0.7240 0.752 (0.373, 1.514), 0.4240
Community care 0.471 (0.241, 0.920), 0.0280 0.464 (0.288, 0.745), 0.0020
Other 0.419 (0.153, 1.149), 0.0910 0.395 (0.166, 0.941), 0.0360
Q8—uses apps in daily clinical practice
No Reference category Reference category
Yes 1.886 (1.341, 2.654), 0.0000 2.010 (1.469, 2.749), 0.0000
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patients’ awareness of their own health (see Fig. 7). Spe-
cifically, RMT data was found to impact on communica-
tion with patients, on HCPs’ understanding of patient 
health state, and on HCPs’ decision-making processes. 
Regression analyses show that HCP views on the impact 
of RMT data vary according to whether respondents use 
apps themselves. This adds to recent research in the area 
of depression care indicating an association between 
level of technology experience and consideration of use 
of apps in clinical practice [25]. Views on the impact of 
RMT data were also found to vary according to clinical 
setting, job role and age.
Our results suggest RMT is currently having a greater 
impact in primary care than in other healthcare sectors. 
A higher proportion of general practitioner respond-
ents reported their patients used devices to monitor 
activity and sleep and manage weight than in other job 
roles. This suggests a greater awareness among GPs than 
among other health care professionals concerning the 
devices patients use, and the purposes for which they 
Table 5 Question 10.3—Does data from patients’ RMT impact your understanding of patient health state between consultations?
Results from logistic regression with multiple imputation. Multiple imputation was used to impute data for this question item for 303 missing entries out of total 1006. 
Bold font indicates significant result
Question content/variable/category Multivariate model Univariate model
Impact of data on understanding of patient health state 
between consultations
OR (95% CI), p OR (95% CI), p
Q3—age
18–30 years 1.088 (0.647, 1.830), 0.7490 1.097 (0.680, 1.770), 0.7040
31–40 years 1.244 (0.821, 1.884), 0.3030 1.233 (0.827, 1.838), 0.3030
41–50 years Reference category Reference category
51–60 years 1.116 (0.766, 1.627), 0.5670 1.101 (0.766, 1.584), 0.6030
Over 60 years 1.433 (0.675, 3.038), 0.3480 1.553 (0.764, 3.158), 0.2240
Q4—specialism
Mental health Reference category Reference category
Neurology 1.077 (0.707, 1.641), 0.7280 1.105 (0.740, 1.651), 0.6240
Not specified 1.421 (0.973, 2.074), 0.0690 1.411 (0.979, 2.035), 0.0650
Q5—job role
Doctor excluding GP Reference category Reference category
Allied health professional 1.063 (0.561, 2.016), 0.8510 0.766 (0.427, 1.376), 0.3720
Not specified 1.535 (0.734, 3.207), 0.2550 1.267 (0.620, 2.591), 0.5160
GP 1.775 (0.813, 3.875), 0.1490 1.786 (1.041, 3.064), 0.0350
Research/healthcare scientist 0.912 (0.340, 2.448), 0.8560 0.805 (0.315, 2.057), 0.6510
Management 0.725 (0.305, 1.724), 0.4660 0.641 (0.278, 1.475), 0.2950
Nursing 1.358 (0.827, 2.231), 0.2270 1.122 (0.710, 1.771), 0.6220
Pharmacy 1.633 (0.380, 7.027), 0.5090 1.755 (0.431, 7.140), 0.4320
Clinical psychology professional 1.374 (0.762, 2.478), 0.2900 1.012 (0.605, 1.693), 0.9640
Student 1.235 (0.251, 6.070), 0.7950 1.285 (0.278, 5.946), 0.7480
Wider healthcare team 1.395 (0.717, 2.716), 0.3270 1.138 (0.616, 2.105), 0.6790
Q6—setting
Primary care Reference category Reference category
Secondary care—hospital inpatient 1.037 (0.495, 2.173), 0.9240 0.788 (0.441, 1.408), 0.4220
Secondary care—hospital outpatient 0.891 (0.422, 1.880), 0.7610 0.678 (0.384, 1.199), 0.1820
Secondary care—MH inpatient 0.954 (0.482, 1.885), 0.8910 0.767 (0.461, 1.277), 0.3080
Secondary care—MH outpatient 0.860 (0.478, 1.547), 0.6150 0.613 (0.401, 0.937), 0.0240
Specialist tertiary care 1.424 (0.626, 3.237), 0.3990 0.941 (0.483, 1.833), 0.8570
Community care 0.725 (0.385, 1.366), 0.3190 0.551 (0.348, 0.871), 0.0110
Other 0.514 (0.175, 1.511), 0.2260 0.370 (0.144, 0.951), 0.0390
Q8—uses apps in daily clinical practice
No Reference category Reference category
Yes 1.760 (1.265, 2.449), 0.0010 1.781 (1.311, 2.418), 0.0000
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may use them. In addition, GPs were significantly more 
likely than other kinds of doctor to indicate that RMT 
data had an impact on their work, on 3 out of 5 questions 
on this topic (see Tables  3, 4, 5, 6 and 7). Furthermore, 
those working in primary care were significantly more 
likely than those in secondary care (mental health outpa-
tient), community care and ‘other’ settings to report that 
RMT data impacted their work, on all five questions on 
this topic. This may be because patients are more likely 
to discuss the data from devices they have bought them-
selves with primary care practitioners, who they see 
more regularly, and for whom relational aspects of their 
work are considered more important. While prior work 
in both Denmark [29] and the UK [20] has shown that 
general practitioners recognise benefits to patient use of 
wearables and apps, the present study has demonstrated 
more precisely how the attitudes of primary care profes-
sionals differ from those in other areas of care.
Our sub-group analysis of job roles that use apps in 
their clinical practice revealed that a larger proportion 
of pharmacists (100%) and medical students (90%) use 
apps in their clinical practice than those in other job 
Table 6 Question 10.4—Does data from patients’ RMT impact patients’ awareness of their own health?
Results from logistic regression with multiple imputation. Multiple imputation was used to impute data for this question item for 282 missing entries out of total 1006. 
Bold font indicates significant result
Question content/variable/category Multivariate model Univariate model
Impact of data on patients’ awareness of their own health OR (95% CI), p OR (95% CI), p
Q3—age
18–30 years 0.861 (0.502, 1.476), 0.5850 0.914 (0.569, 1.467), 0.7080
31–40 years 1.237 (0.790, 1.937), 0.3530 1.204 (0.790, 1.837), 0.3880
41–50 years Reference category Reference category
51–60 years 1.147 (0.752, 1.750), 0.5250 1.113 (0.745, 1.660), 0.6010
Over 60 years 1.423 (0.591, 3.426), 0.4310 1.450 (0.645, 3.262), 0.3680
Q4—specialism
Mental health Reference category Reference category
Neurology 0.805 (0.500, 1.297), 0.3720 0.831 (0.531, 1.298), 0.4150
Not specified 0.910 (0.609, 1.360), 0.6460 0.958 (0.656, 1.398), 0.8240
Q5—job role
Doctor excluding GP Reference category Reference category
Allied health professional 1.102 (0.566, 2.143), 0.7750 0.814 (0.448, 1.476), 0.4970
Not specified 0.955 (0.432, 2.112), 0.9090 0.835 (0.391, 1.783), 0.6410
GP 0.834 (0.297, 2.345), 0.7310 2.501 (1.280, 4.887), 0.0070
Research/healthcare scientist 0.859 (0.306, 2.408), 0.7720 0.688 (0.257, 1.840), 0.4560
Management 0.645 (0.279, 1.489), 0.3040 0.587 (0.262, 1.312), 0.1940
Nursing 1.089 (0.640, 1.854), 0.7520 0.994 (0.610, 1.620), 0.9820
Pharmacy 0.429 (0.108, 1.700), 0.2280 0.457 (0.125, 1.665), 0.2350
Clinical psychology professional 1.744 (0.884, 3.440), 0.1090 1.558 (0.838, 2.899), 0.1610
Student 1.507 (0.272, 8.346), 0.6380 1.023 (0.197, 5.308), 0.9780
Wider healthcare team 0.771 (0.378, 1.574), 0.4740 0.649 (0.339, 1.242), 0.1920
Q6—setting
Primary care Reference category Reference category
Secondary care—hospital inpatient 0.252 (0.101, 0.627), 0.0030 0.251 (0.130, 0.486), 0.0000
Secondary care—hospital outpatient 0.403 (0.153, 1.063), 0.0660 0.422 (0.207, 0.859), 0.0170
Secondary care—MH inpatient 0.272 (0.118, 0.631), 0.0020 0.261 (0.146, 0.465), 0.0000
Secondary Care—MH outpatient 0.291 (0.130, 0.651), 0.0030 0.309 (0.184, 0.517), 0.0000
Specialist tertiary care 0.414 (0.140, 1.217), 0.1090 0.437 (0.191, 1.002), 0.0500
Community care 0.240 (0.103, 0.559), 0.0010 0.251 (0.142, 0.442), 0.0000
Other 0.222 (0.069, 0.709), 0.0110 0.210 (0.084, 0.525), 0.0010
Q8—uses apps in daily clinical practice
No Reference category Reference category
Yes 1.678 (1.178, 2.390), 0.0040 1.496 (1.091, 2.051), 0.0120
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categories. The most commonly used app types by these 
groups were prescribing/dosing apps and guidelines 
apps, respectively. However, it is important to note that 
these job roles were only represented by a small number 
of respondents relative to other job roles (15 pharmacists 
and 10 medical students), meaning it is possible that only 
those very most interested in the application of technol-
ogy chose to take part in this study.
Our data on the type of RMT device used by patients 
for each health-related purpose (Fig. 6) showed that use 
of wearables was less prevalent than use of smartphones 
for certain purposes (weight management, setting per-
sonal health goals, monitoring mood). Recalling that this 
survey was conducted with HCPs rather than patients, 
it is possible that HCPs are unaware that their patients 
use wearables in these ways where patients do not deem 
it relevant to inform clinicians of this, and thus their use 
may be under-represented in these survey results. Wear-
ables are not as ubiquitous as smartphones, and this may 
also explain the lower reported use of these for health-
related purposes. Another possible explanation is that 
wearable devices have smaller screens and lack the space 
Table 7 Question 10.5—Does data from patients’ RMT impact your decision-making processes during consultation?
Results from logistic regression with multiple imputation. Multiple imputation was used to impute data for this question item for 306 missing entries out of total 1006. 
Bold font indicates significant result
Question content/variable/category Multivariate model Univariate model
Impact of data on decision‑making during consultation OR (95% CI), p OR (95% CI), p
Q3—age
18–30 years 0.593 (0.358, 0.983), 0.0430 0.610 (0.382, 0.976), 0.0390
31–40 years 0.724 (0.474, 1.105), 0.1340 0.695 (0.461, 1.048), 0.0830
41–50 years Reference category Reference category
51–60 years 0.835 (0.555, 1.257), 0.3870 0.816 (0.548, 1.214), 0.3150
Over 60 years 0.696 (0.334, 1.448), 0.3310 0.767 (0.383, 1.533), 0.4520
Q4—specialism
Mental health Reference category Reference category
Neurology 0.784 (0.514, 1.197), 0.2600 0.779 (0.520, 1.168), 0.2270
Not specified 0.990 (0.695, 1.411), 0.9560 0.977 (0.696, 1.371), 0.8920
Q5—job role
Doctor excluding GP Reference category Reference category
Allied health professional 1.014 (0.552, 1.865), 0.9640 0.736 (0.419, 1.292), 0.2850
Not specified 0.948 (0.438, 2.053), 0.8930 0.806 (0.385, 1.688), 0.5670
GP 0.494 (0.221, 1.101), 0.0850 0.904 (0.519, 1.574), 0.7210
Research/healthcare scientist 0.504 (0.169, 1.506), 0.2200 0.382 (0.133, 1.097), 0.0740
Management 0.661 (0.273, 1.602), 0.3590 0.620 (0.268, 1.431), 0.2620
Nursing 1.090 (0.648, 1.834), 0.7450 0.938 (0.580, 1.515), 0.7920
Pharmacy 0.975 (0.247, 3.856), 0.9720 1.182 (0.314, 4.457), 0.8040
Clinical psychology professional 0.772 (0.414, 1.439), 0.4140 0.627 (0.362, 1.086), 0.0960
Student 0.789 (0.133, 4.662), 0.7930 0.521 (0.098, 2.776), 0.4450
Wider healthcare team 0.854 (0.437, 1.670), 0.6450 0.689 (0.367, 1.293), 0.2460
Q6—setting
Primary care Reference category Reference category
Secondary care—hospital inpatient 0.485 (0.226, 1.040), 0.0630 0.703 (0.392, 1.260), 0.2360
Secondary care—hospital outpatient 0.532 (0.247, 1.146), 0.1070 0.830 (0.468, 1.473), 0.5240
Secondary care—MH inpatient 0.571 (0.287, 1.136), 0.1100 0.823 (0.498, 1.359), 0.4470
Secondary care—MH outpatient 0.426 (0.236, 0.769), 0.0050 0.576 (0.376, 0.882), 0.0110
Specialist tertiary care 0.885 (0.369, 2.120), 0.7830 1.233 (0.606, 2.510), 0.5630
Community care 0.415 (0.219, 0.789), 0.0070 0.629 (0.398, 0.994), 0.0470
Other 0.266 (0.091, 0.782), 0.0160 0.384 (0.150, 0.982), 0.0460
Q8—uses apps in daily clinical practice
No Reference category Reference category
Yes 1.600 (1.129, 2.268), 0.0080 1.666 (1.195, 2.323), 0.0030
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to incorporate an easy method for manual data entry and 
are thus better suited to ‘passive’ means of data collection 
than ‘active’ means.
In comparison to other health conditions, this survey, 
targeting HCPs working in the care of people with MS, 
epilepsy or depression, demonstrated a higher proportion 
of respondents reporting patients using RMT for health 
related purposes (78%) than was the case in studies on 
diabetes (type 1: < 60%, type 2: ~ 33%) [1] and hyperten-
sion (< 50%) [2]. Given the recency of these prior studies, 
it is unlikely that this is simply a result of technologies 
becoming more widespread, and may reflect a difference 
in how these conditions are managed, with both blood 
pressure and blood sugar being measured using bespoke 
(non-wearable) devices, and therefore not requiring a 
smartphone app to be able to measure the symptoms of 
these conditions.
Our work is novel in exploring views on the application 
of these technologies in the care of people with epilepsy, 
MS, or depression, from a large sample. This evidence 
adds to a growing body of work understanding the rela-
tionships between healthcare technology use, compe-
tence and adoption by healthcare professionals. Recent 
work by Vallo et al. [30] indicates that adoption and use 
of digital technology are “related to perceived perfor-
mance, social influence and organisational context” and 
the role of ICT [Information and Communication Tech-
nology] in clinical professional development. This work 
highlights the need for a holistic service design approach 
[31] to reduce external and internal barriers to adoption 
and optimise the benefits and professional competence of 
use of these technologies in practice [32].
Recommendations for future work
While HCPs reported using apps, some of the app names 
they reported appear to be patient-facing, and it is not 
clear from our data whether they are using these apps 
themselves or are recommending these to their patients. 
We cannot tell from our study the extent to which 
apps and wearables are prescribed or recommended to 
patients by healthcare professionals. In the UK, some 
smartphone apps are now highlighted in the NHS apps 
library [33], and the National Institute for Health and 
Care Excellence (NICE) has issued guidance that HCPs 
consider digital mobile health interventions, including 
smartphone apps, for behaviour change [34]. However, 
the present study has not been able to ascertain how 
many HCPs actively recommend these to their patients 
and this is an interesting question for future work. In 
other European countries including Germany and Swe-
den, governments incentivise HCPs to recommend 
digital solutions to their patients [35]. Further work 
could also usefully compare use of treatment pathways 
involving apps and wearables in countries with differ-
ent incentivisation policies to understand the benefits of 
these approaches. There are also questions around the 
regulation of apps and the effect of regulation on their 
adoption that could be usefully explored.
Recently, NHS guidance has been aimed at primary and 
secondary care services reducing face-to-face appoint-
ments during the COVID-19 pandemic [23, 36] and there 
is some suggestion that healthcare professionals may 
have become more favourably disposed to the use of digi-
tal technologies to support their clinical practice during 
this period [37]. However, this evidence relates largely 
to the use of video conferencing software and telephone 
consultations rather than the use of wearables and apps 
to generate data on behavioural and physiological aspects 
of health, although these are beginning to be evaluated 
in practice. Given that clinicians would be required to 
review the data from such RMT on a digital device (e.g. 
computer) even if patients were present at a face-to-face 
appointment, it is not clear whether the recent reduc-
tion in face-to-face appointments would cause a change 
of attitudes towards the use of this data in practice. Fur-
ther work would be required to understand precisely how 
views on these specific areas may have changed or not 
because of the reorganisation of care for non-COVID-19 
patients during the pandemic.
Strengths and limitations
A key strength of this study is the large sample size, with 
over 1000 respondents. Another is the exploration of the 
impact that RMT data has on patient care. The applica-
tion of regression techniques has enabled us to control 
for demographic factors when exploring the variation 
in these views. Despite a coordinated effort to facilitate 
responses from clinicians working outside of the UK 
(translation into multiple European languages, adver-
tisement via social media, network connections), the 
proportion of those working in other countries among 
respondents to the survey was small. However, we were 
able to reach a representative sample of respondents 
from different age groups, job roles and clinical settings, 
which has enabled sub-group analyses of the views and 
experiences presented. There is some risk that the self-
selecting sample for this study were those most interested 
in the use of technology and this may mean that views 
expressed are more positive than is the case across all 
healthcare professionals. A small percentage of respond-
ents (6%) were from management or healthcare science 
roles where their contact with patients, and therefore 
their understanding of factors relevant to the application 
of RMT, may be more limited. As an exploratory study, 
the data were analysed without multiplicity adjustment 
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and results were mainly interpreted for exploratory and 
not confirmatory purposes [38].
Conclusions
This survey study achieved its aim of eliciting opinions 
and experiences from a large sample of HCPs working in 
the care of patients with epilepsy, MS or depression. Our 
main objectives in the present work were: (i) to deter-
mine the extent of smartphone app usage among health 
care professionals; (ii) to determine the extent of HCP 
experience of managing patients’ use of RMT; and (iii) to 
understand the impact of patient RMT usage on HCPs’ 
work, including how this may vary by demographic fac-
tors. The results show that prior to the COVID-19 pan-
demic, smartphone apps were already widely used by 
more than half of HCPs (objective i), and RMT was used 
by more than three quarters of their patients (objec-
tive ii). HCPs widely believed that the data from RMT 
impacted their clinical practice, although there is some 
evidence that their views vary according to demographic 
and technology usage factors (objective iii). We consider 
it unlikely that views on the usefulness of the data from 
RMT will be substantially different after the pandemic, 
given similar practical requirements for its application 
in both face-to-face and remote consultations, although 
further research would be needed to test this hypothesis. 
We do expect that more HCPs will become more famil-
iar with RMT and that adoption of mobile platforms will 
become more prevalent in routine health and social care 
settings in the aftermath of COVID-19.
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